Introduction {#sec1}
============

Fanconi anemia (FA) is an autosomal recessive disorder associated with birth defects, progressive bone marrow failure, hematopoietic stem cell (HSC) depletion, and cancer predisposition. FA is caused by a disrupted FA-BRCA network and is genetically heterogeneous, with at least 16 complementation groups and respective genes identified so far ([@bib17]).

Progressive bone marrow failure is the primary cause of morbidity and mortality in FA patients ([@bib19]). Most patients develop marrow dysfunction within the first decade of life. The symptoms range from mild cytopenia in any lineage to severe aplastic anemia, often initially with thrombocytopenia ([@bib31]). Red cell macrocytosis is quite common in FA patients and usually precedes the onset of thrombocytopenia.

HSC transplantation is the only curative treatment for bone marrow failure in FA. However, androgens have also been widely used to treat cytopenia in FA, especially for patients unable to proceed to transplant or patients with high transplant risk. The most commonly used androgen is oxymetholone (OXM), which is an anabolic-androgenic steroid and a synthetic derivative of testosterone ([@bib31]). Androgen therapy raises blood counts in ∼50% to 70% of individuals with FA and also works for other forms of aplastic anemia ([@bib6]).

Despite a long history of androgen use in bone marrow failure syndromes, the mechanism whereby these molecules boost blood counts remains enigmatic ([@bib4]). It has been suggested that androgens stimulate erythropoiesis through an increase in the production of erythropoietin (EPO). However, more recent studies have found no close correlation between androgens and EPO levels ([@bib4]), leading others to speculate that androgens might have a direct effect on bone marrow ([@bib36]). One recent in vitro study suggested that androgens act by increasing telomerase activity and extending the lifespan of CD34^+^ stem/progenitor cells ([@bib2]).

Multiple murine models of FA are available. Among them, *Fancd2*^*−/−*^ mice, *Fancp*^*−/−*^ mice, and *Fancc-Fancg* double knockout mice represent human FA patient phenotypes more closely than the others ([@bib5; @bib13; @bib27; @bib28; @bib40]). *Fancd2*^*−/−*^ mice recapitulate the characteristic tumor susceptibility of FA and show an ∼2-fold decrease in hematopoietic stem and progenitor cell (HSPC) populations and a very poor long-term repopulating capacity of bone marrow ([@bib27; @bib40]). Despite this, the mice have no obvious anemia in their peripheral blood at age 6 months, except for lower platelet counts. Here, however, we found that 18-month-old *Fancd2*^*−/−*^ mice developed spontaneous pancytopenia. We then set out to investigate how OXM benefits FA patients using this aged *Fancd2*^*−/−*^ mouse model.

Results {#sec2}
=======

Eighteen-Month-Old Fancd2^*−*/*−*^ Mice Have Pancytopenia and Respond to OXM Treatment {#sec2.1}
--------------------------------------------------------------------------------------

We previously reported that 4- to 6-month-old *Fancd2*^*−/−*^ mice have reduced numbers of HSCs with no evidence for anemia in peripheral blood except for low platelet counts ([@bib40; @bib41]). A follow-up investigation on a larger cohort of mice at the same age confirmed normal white and red blood cell counts and low platelet counts and also revealed a slight but significant elevation of mean corpuscular volume (MCV), which is a characteristic clinical phenotype of human FA patients ([Table S1](#app3){ref-type="sec"} available online) ([@bib31]). To track the progression of these defects, we followed a cohort of *Fancd2*^*−/−*^ and WT mice until 18 months of age. Similar to the findings in our earlier report ([@bib13]), 5 of 17 mutant mice developed tumors (with 3 of them being ovarian tumors) during this time period, whereas only 1 of 20 WT mice had a tumor. Animals with tumors were excluded from further analysis. We found that cancer-free 18-month-old *Fancd2*^*−/−*^ mice had developed spontaneous pancytopenia with red blood cells, white blood cells, hemoglobin levels, and platelet counts all below the normal ranges seen in age-matched WT controls ([Figure 1](#fig1){ref-type="fig"}A). *Fancd2*^*−/−*^ mice also showed a highly elevated MCV compared with WT controls and a reduction in bone marrow cellularity ranging from 25% to 75% ([Figures 1](#fig1){ref-type="fig"}A and 1B). Most of the old *Fancd2*^*−/−*^ mice showed spleen defects, with 6 of 10 mice displaying small spleens and 2 of 10 mice having splenomegaly ([Figure 1](#fig1){ref-type="fig"}C). We consistently observed Howell-Jolly bodies, which are often associated with decreased splenic function, in peripheral blood smears ([Figure 1](#fig1){ref-type="fig"}D). Large, oval-shaped macrocytes and polychromatic cells (bluish red blood cells in hematoxylin and eosin \[H&E\] staining) were also visible in the peripheral blood of 18-month-old *Fancd2*^*−/−*^ mice ([Figure 1](#fig1){ref-type="fig"}D). In contrast, they were rare in age-matched WT mice. Four of 10 of the old *Fancd2*^*−/−*^ mice had thickening of the cortical bone and narrowing of the marrow cavity typical of osteopetrosis ([Figure 1](#fig1){ref-type="fig"}E).

We next wished to test whether OXM could improve these FA-associated hematologic abnormalities. The OXM dose was chosen to be equivalent to ∼80% of the maximum dose for human patients ([@bib31]). To assure that the compound had the expected biological activity, *Fancd2*^*−/−*^ and WT mice were treated with either OXM-supplemented or placebo chow for 4 months. At harvest OXM-treated animals had larger kidneys ([Figures S1](#app3){ref-type="sec"}A and S1B), indicating that the androgenic dose was sufficient and biologically active ([@bib32]). Androgen is known to downregulate renal ornithine aminotransferase gene *Oat* ([@bib20]). As expected, *Oat* mRNA expression level in OXM-treated mice was reduced by 75% ([Figure S1](#app3){ref-type="sec"}C), further confirming the bioactivity of the OXM diet.

We then treated cohorts of 1-month-old *Fancd2*^*−/−*^ mice and WT littermate controls with either OXM-supplemented chow or placebo diet and monitored them until age 18 months. Importantly, mice on OXM exhibited clearly improved hematological parameters, including platelet counts, red blood cell counts, hematocrit, and hemoglobin levels ([Figures 2](#fig2){ref-type="fig"}A and 2B), albeit with no significant changes in white blood cell counts. The long-term OXM treatment also partially corrected the macrocytosis typical for FA. Collectively, these results indicate that 18-month-old *Fancd2*^*−/−*^ mice recapitulated FA patient phenotypes and that OXM benefited *Fancd2*^*−/−*^ mice at the level of peripheral blood in the same way it does for human patients.

Long-Term OXM Treatment Leads to Stem Cell Exhaustion in Both Fancd2^*−*/*−*^ and WT Mice {#sec2.2}
-----------------------------------------------------------------------------------------

We then sought to determine the effect of long-term OXM administration on bone marrow HSPCs, immunophenotypically defined as c-KIT^+^SCA-1^+^LIN^*−*^ (KSL) cells. Cohorts of 1-month-old *Fancd2*^*−/−*^ and WT mice were treated with either OXM-supplemented chow or placebo diet and monitored until age 18 months. CD34^*−*^KSL cells, a population enriched with long-term HSCs, were then quantitated by flow cytometry ([Figure 3](#fig3){ref-type="fig"}A). First, we compared the frequencies of CD34^*−*^KSL cells in these old mice with those in young mice. As shown in [Figure 3](#fig3){ref-type="fig"}B, 18-month-old *Fancd2*^*−/−*^ mice had significantly fewer CD34^*−*^KSL cells than 4-month-old *Fancd2*^*−/−*^ mice, indicating a progressive attrition of the HSC pool during the aging process. We then examined the effect of OXM on the frequencies of CD34^*−*^KSL cells. Surprisingly, the CD34^*−*^KSL proportions of the nucleated bone marrow cells in OXM-treated *Fancd2*^*−/−*^ and WT mice (0.005% and 0.019%, respectively) were significantly lower (p \< 0.05 for WT and p \< 0.02 for *Fancd2*^*−/−*^ mice) than those in placebo-treated *Fancd2*^*−/−*^ and WT mice (0.009% and 0.027%, respectively), as shown in [Figure 3](#fig3){ref-type="fig"}B. These results indicate that long-term OXM administration might cause stem cell exhaustion.

We next evaluated the function of the HSCs from these older mice with the competitive repopulation assay depicted in [Figure 3](#fig3){ref-type="fig"}C. Bone marrow cells of OXM-treated mice were transplanted along with a fixed ratio of *ROSA26*^*Tg/O*^ genetically marked bone marrow cells (as competitors) into lethally irradiated *Fancc*^*−/−*^ mice. Six months after transplantation, peripheral blood chimerism was measured using quantitative PCR for the three genotypes. At transplantation, the donor mix contained *Fancd2*^*−/−*^ bone marrow cells and *ROSA26*^*Tg/O*^ bone marrow cells at a 3:1 (*Fancd2*^*−/−*^ versus *ROSA26*^*Tg/O*^) ratio. Six months after transplantation, this ratio for placebo-treated *Fancd2*^*−/−*^ bone marrow dropped to 1:150 ([Figure 3](#fig3){ref-type="fig"}D). This decrease in repopulating ability is significantly worse than that of 3-month-old *Fancd2*^*−/−*^ mice under similar experimental settings previously reported by us ([@bib40; @bib41]) and suggests a progressive deterioration of long-term HSC function in *Fancd2*^*−/−*^ mice as they age. In contrast, placebo-treated WT bone marrow cells only suffered marginal loss in their HSC repopulating capacity with aging ([Figure 3](#fig3){ref-type="fig"}D). Interestingly and importantly, the long-term HSC repopulating capacities of both *Fancd2*^*−/−*^ and WT bone marrow were reduced by ∼40% (p \< 0.05) in OXM-treatment groups ([Figure 3](#fig3){ref-type="fig"}D). Taken together, these data indicate that OXM administration leads to loss of long-term HSC function.

OXM Selectively Stimulates HSPC Proliferation in Both Fancd2^*−*/*−*^ and WT Mice {#sec2.3}
---------------------------------------------------------------------------------

Increased cell cycle entry has been associated with eventual stem cell exhaustion in several models ([@bib26]). To understand what drove the loss of long-term HSC function after chronic OXM administration, the cell cycle status of HSPCs in OXM-treated mice was determined. *Fancd2*^*−/−*^ mice and controls were given either OXM diet or placebo for 4 months starting at 1 month of age. We previously reported that *Fancd2*^*−/−*^ KSL cells lose quiescence and display enhanced cell cycle entry ([@bib40; @bib41]). Four months of OXM therapy were insufficient to change the size of HSPC pool or affect HSPC function in the colony-forming unit-spleen assay (data not shown). Nonetheless, cell cycle analysis at this time revealed that OXM administration profoundly stimulated the proliferation of HSPCs. The cell cycle status was measured with a well-established method combining Hoechst 33342 staining (for DNA content) with intracellular KI67 expression (expressed only in cycling cells, not in quiescent G0 cells). As shown in [Figure 4](#fig4){ref-type="fig"}A, both *Fancd2*^*−/−*^ and *Fancd2*^*+/+*^ mice on OXM treatment had substantially fewer quiescent G0 KSL cells and a higher percentage of actively cycling ones (S-G2-M phases of the cell cycle) than their placebo-treated littermate controls. Upon OXM administration, the average G0 percentage of KSL cells in *Fancd2*^*−/−*^ and *Fancd2*^*+/+*^ mice dropped from 24.1% and 48.4% to 14.0% and 35.1%, respectively (p \< 0.0001 for both) ([Figure 4](#fig4){ref-type="fig"}B). Correspondingly, the average S-G2-M proportions of KSL cells increased from 16.2% to 22.9% in mutant animals (p \< 0.002) and from 9.4% to 13.0% in WT mice (p \< 0.05) ([Figure 4](#fig4){ref-type="fig"}B). These results indicate that OXM further enhanced the already accelerated proliferation of FA HSPCs and drove them into active cycling.

We then determined whether the proliferation-enhancing effect of OXM was specific only to HSPCs. The cell cycle profiles of more mature lineage-positive (LIN^+^) cells from the same mice were evaluated. We found that *Fancd2*^*−/−*^ LIN^+^ cells had a normal cell cycle status ([Figure 4](#fig4){ref-type="fig"}C). Interestingly, the G0 and S-G2-M proportions of LIN^+^ cells were unchanged after OXM administration in both mutant and WT ([Figures 4](#fig4){ref-type="fig"}C and [S2](#app3){ref-type="sec"}). In addition, we also examined the cell cycle status of LIN^*−*^c-KIT^+^SCA-1^*−*^ cells, a population that includes common myeloid progenitors, granulocyte/monocyte progenitors, megakaryocyte/erythroid progenitors, and other cells. Although *Fancd2*^*−/−*^ LIN^*−*^c-KIT^+^SCA-1^*−*^ cells showed slightly reduced quiescence compared with their WT counterparts, neither *Fancd2*^*−/−*^ nor WT LIN^*−*^c-KIT^+^SCA-1^*−*^ cells showed increased proliferation in response to OXM administration ([Figure S3](#app3){ref-type="sec"}). These results indicated that OXM did not broadly stimulate blood cell proliferation, but acted selectively at the level of HSPCs.

RNA-Seq Analysis Discovers Transcriptional Changes in Fancd2^*−*/*−*^ HSPCs {#sec2.4}
---------------------------------------------------------------------------

We next wished to compare the transcriptomes of Fanconi mutant and normal HSPCs. KSL cells were sorted by flow cytometry after 3 months of OXM administration and used for RNA-Seq gene expression analysis ([@bib39]). Three individual samples (pooled from five mice for each sample) were processed for each experimental condition, with combined reads (aligned to unique RefSeq genes) per condition in the range of 100 to 200 million. As shown in [Table S2](#mmc2){ref-type="supplementary-material"}, *Fancd2*^*−/−*^ KSL cells showed clear changes in mRNA expression profiles compared with WT controls: 430 genes were downregulated by more than 1.5-fold, whereas 159 genes were upregulated. As expected from previous work ([@bib13]), we observed a 2.5-fold reduction of *Fancd2* mRNA expression level in *Fancd2*^*−/−*^ KSL cells, confirming the reliability of the RNA-Seq analysis. Whole bone marrow cells were also analyzed in parallel; genes enriched in KSL cells as compared with whole bone marrow cells are listed in [Table S3](#mmc3){ref-type="supplementary-material"}. The transcriptional downregulation (by 1.8-fold) of *Cdkn1c* in *Fancd2*^*−/−*^ KSL cells is particularly interesting since its protein product p57 is critically required for maintaining quiescence in long-term HSCs ([@bib37]). Consistent with its important function in HSCs, our data showed that *Cdkn1c* transcript was enriched by 23-fold in KSL cells as compared with whole bone marrow cells ([Table S3](#mmc3){ref-type="supplementary-material"}). In addition, the critical DNA-damage response gene Rad51 was also upregulated in *Fancd2*^*−/−*^ KSL cells as expected since FA cells often show persistent DNA damage foci due to insufficient DNA interstrand crosslink repair.

Gene ontology analysis revealed key pathways to be significantly altered in *Fancd2*^*−/−*^ KSL cells (summarized in [Table 1](#tbl1){ref-type="table"}). Consistent with the abnormal cell cycle status discovered by flow cytometry analysis, the pathways of cell cycle activation and its regulation were enhanced in *Fancd2*^*−/−*^ KSL cells. Specifically, many cell cycle genes showed transcriptional changes in *Fancd2*^*−/−*^ KSL cells, including the upregulation of *Cdk1*, *Ccna2*, *Ccnb1*, *Ccnb2*, *Ccnd1*, *Cdc25C*, *Cdkn3*, *Cdca3*, *Cdca8*, *Cks1b*, *Nek2*, *Birc5*, *Cdca5*, *Mad2l1*, *Pttg1*, and *Aurka* ([Table S4](#app3){ref-type="sec"}). Some of these genes are known cell cycle regulators in HSCs ([@bib29; @bib37]). Surprisingly, we also noticed that a group of genes involved in immune responses and inflammation, comprising *Cfp* (Properdin), *Socs2*, *Ccr1*, *Ccr2*, *Ccr5*, *Chga* (Chromogranin A), *Ifi30* (Interferon Gamma-Inducible Protein 30), *Lgmn*, *Txn*, and *Sell* (selectin L), were upregulated in *Fancd2*^*−/−*^ KSL cells ([Tables 1](#tbl1){ref-type="table"} and [S4](#app3){ref-type="sec"}).

Changes in mRNA Expression Profile in HSPCs in Response to OXM Administration Reveal a Mechanism behind OXM's Proliferation-Stimulating Effect {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------------------------

In order to interrogate the mechanism underlying the cell cycle changes induced by OXM, we performed RNA-Seq on HSPCs from the placebo and OXM treatment groups. Considering that the proliferation-enhancing effect of OXM was observed in both *Fancd2* mutant and WT mice, we focused our analysis on OXM-altered genes shared by both genotypes. Only four genes ([Table 2](#tbl2){ref-type="table"}) changed their expression levels significantly after OXM administration in both *Fancd2*^*−/−*^ and WT mice. Both *mKi67* and *Cenpf* are cell cycle-regulated genes and proliferation markers. In fact, the *mKi67*-encoded protein is the antigen recognized by anti-KI67 antibody, the same antibody used in our cell cycle analysis. The RNA-Seq data demonstrated that both genes were expressed at lower levels in KSL cells, as compared with whole bone marrow cells, and were mildly but significantly upregulated after OXM administration, further confirming our observation above that OXM stimulates the proliferation of HSPCs in both *Fancd2*^*−/−*^ and WT mice.

Two genes, *Spp1* and *Oasl2*, were significantly downregulated after OXM administration. *Spp1* in particular was affected and was suppressed over 10-fold ([Table 2](#tbl2){ref-type="table"}). *Spp1* was expressed at similar levels in both HSPCs and whole bone marrow cells ([Table S3](#mmc3){ref-type="supplementary-material"}) and encodes secreted phosphoprotein 1 (also known as osteopontin), a cytokine known to upregulate the expression of certain interferons and interleukins. The other gene *Oasl2* was enriched 11-fold in HSPCs compared with whole bone marrow cells ([Table S3](#mmc3){ref-type="supplementary-material"}). *Oasl2* encodes 2′-5′ oligoadenylate synthetase-like 2 and belongs to a highly conserved family of interferon-induced enzymes ([@bib14]). Since both genes are known to inhibit proliferation ([@bib18; @bib25]), it is plausible that OXM-mediated suppression of these genes underlies its proliferation-promoting effects.

It is worth noting that no expression changes in *mTert* RNA expression levels were detected in response to OXM administration ([Table S5](#app3){ref-type="sec"}), although *mTert* mRNA was enriched 13-fold in HSPCs of both *Fancd2*^*−/−*^ and WT mice ([Table S3](#mmc3){ref-type="supplementary-material"}). Therefore, the induction of telomerase ([@bib2]) is unlikely to underlie the activity of OXM during chronic administration.

OXM Suppresses Spp1 Transcription in an Androgen Receptor-Dependent Manner {#sec2.6}
--------------------------------------------------------------------------

Although it has never been reported that *Spp1* is an androgen-target gene, a genome-wide profiling of androgen receptor (AR) binding identified one AR target site in intron 3 of the human *SPP1* gene ([Figure S4](#app3){ref-type="sec"}A) ([@bib22]). Bioinformatics analysis using UCSC PhyloP basewise conservation tool (<http://genome.ucsc.edu/>) further revealed that this AR target site was highly conserved across different species ([Figure S4](#app3){ref-type="sec"}B). Furthermore, a BLAT search with the human AR target sequence returned an intronic sequence with 84% DNA sequence identity in the mouse *Spp1* gene. The *Spp1*-encoded osteopontin is known to be produced by osteoclasts and osteoblasts ([@bib25; @bib35]), but is also expressed in some soft tissues such as the kidney ([@bib15]). Since osteoblasts are difficult to purify from bone marrow, we tested *Spp1* transcriptional changes by quantitative RT-PCR in cultured 7F2 mouse osteoblasts in vitro. As shown in [Figure 5](#fig5){ref-type="fig"}A, 24 hr of treatment with OXM significantly reduced *Spp1* mRNA level in osteoblasts (p \< 0.005). We also measured *Spp1* gene expression levels in vivo by quantitative RT-PCR. As shown in [Figure 5](#fig5){ref-type="fig"}B, *Spp1* mRNA levels in the kidneys of chronic OXM-treated mice were 80% lower than those in placebo-treated, gender-matched controls (p \< 0.0001). Immunohistochemistry staining of bone sections with an anti-Spp1 antibody confirmed the downregulation of Spp1 in the bone samples from OXM-treated mice ([Figure S4](#app3){ref-type="sec"}C).

Moreover, the suppression of *Spp1* transcription by OXM was dependent on the AR. *Spp1* mRNA levels were unchanged by OXM treatment in AR-deficient mice of C57BL/6J strain background (p = 0.77; [Figure 5](#fig5){ref-type="fig"}C). In contrast, WT mice of the same strain showed clear OXM-mediated suppression of *Spp1* transcription (p \< 0.0001; [Figure 5](#fig5){ref-type="fig"}C).

To further understand the correlation between *Spp1* mRNA levels and HSPC proliferation, we then treated AR-deficient mice with OXM for 4 months and examined the cell cycle profiles of their KSL cells. 44.5% (±2.6%) of KSL cells in OXM-treated *AR*^*−/−*^ mice were in the G0 stage of the cell cycle, similar to 43.8% (±2.5%) observed in placebo-treated *AR*^*−/−*^ mice (p = 0.84; [Figure 5](#fig5){ref-type="fig"}D). Similarly, the proportions of KSL cells in S-G2-M phase in both OXM-treated and placebo-treated *AR*^*−/−*^ mice were at the same levels (p = 0.92; [Figure 5](#fig5){ref-type="fig"}D). In contrast, in WT control mice of the same C57BL/6J background, significant loss of quiescence and enhanced cycling in OXM-treated group (p \< 0.05; [Figure 5](#fig5){ref-type="fig"}D) were seen. Taken together, these results suggest that OXM stimulates HSPC proliferation through AR-mediated transcriptional suppression of *Spp1*.

Changes in mRNA Expression Profile in Basophilic Erythroblasts in Response to OXM Rule Out an EPO-Mediated Mechanism of Action by OXM {#sec2.7}
-------------------------------------------------------------------------------------------------------------------------------------

Finally, we sought to test the previously proposed hypothesis that OXM might activate the EPO pathway in early erythroid progenitors to enhance erythropoiesis ([@bib4]). A group of WT mice was injected with EPO for 3 consecutive days. Complete blood count analysis revealed that the mice on EPO treatment showed higher hemoglobin, an effect similar to that of OXM ([Figure S5](#app3){ref-type="sec"}A). However, the EPO-treated mice also had higher MCV levels than the placebo-treated controls, a known phenomenon caused by the shift of large, immature reticulocytes into circulation as a consequence of EPO-stimulated stress erythropoiesis ([@bib7]). The macrocytosis effect from EPO was in clear contrast to OXM's ability to alleviate macrocytosis under our experimental conditions, suggesting a divergence between the two drugs' mechanisms of action in promoting erythropoiesis.

In addition, the serum levels of EPO in mice on OXM or placebo were measured, and no difference was found ([Figure S5](#app3){ref-type="sec"}B), further indicating that OXM did not function through the activation of the EPO pathway.

In order to further understand this issue and identify any potential targets of OXM in erythroid progenitors, we next sorted TER119^high^/CD71^high^/FSC^high^ basophilic erythroblasts by flow cytometry and investigated the differential mRNA expression profiles with and without OXM administration in WT mice. Basophilic erythroblasts were chosen because this population expresses abundant Epo receptor ([@bib33]). OXM had no effect on the abundance of this population (data not shown). No significant differences at all in gene expression were found between OXM-treated WT erythroid progenitors and their placebo-treated counterparts, with no gene displaying an expression change higher than 1.2-fold. Importantly, no upregulation of EPO-inducible genes such as *Socs1*, *Socs2*, *Socs3*, and *Cish* ([@bib16]) was seen in WT mice treated with OXM ([Table S6](#app3){ref-type="sec"}). In addition, there was no differential expression of the well-known EPO target transferrin receptor or any other major players of the Epo-R signaling network such as *Bcl2l1*, *Cdc25a*, *Btg3*, *Ccnd2*, *Lyl1*, *Pim3*, and *Tnfrsf13c* ([@bib34]) ([Table S6](#app3){ref-type="sec"}). These results further confirm that EPO does not play a role in the action of OXM in the erythroid lineage.

It is also important to mention that *Spp1* mRNA expression was undetectable in basophilic erythroblasts ([Table S7](#app3){ref-type="sec"}), whereas it was robustly expressed in HSPCs.

Discussion {#sec3}
==========

Although OXM has been used for patients with aplastic anemia including FA for many years, its mechanism of action remains poorly understood. The studies described herein provide significant information on how this widely used drug affects hematopoiesis and exerts therapeutic benefit. We found that OXM significantly reduced quiescence and promoted proliferation in KSL hematopoietic stem/progenitor cells. This effect was not specific to FA HSPCs, but affected WT mice just as strongly. The percentage of actively cycling cells increased by at least 50% in both genotypes. Interestingly, the effect of OXM on the cell cycle was specific only to HSPC in both mutant mice and controls. Other hematopoietic lineages in the bone marrow did not divide more frequently in response to the drug. This finding indicates that OXM administration has a direct effect on the HSPC compartment and is consistent with the fact that the drug is known to increase the numbers of all blood lineages in humans, including red blood cells, platelets, and neutrophils ([@bib31]). Although the HSPCs clearly cycle more rapidly on OXM, the number of immunophenotypically defined stem cells did not increase in either mutants or WT mice. This suggests that the newly generated cells rapidly feed into the progenitor compartment rather than generating new stem cells by self-renewal. In fact, our data show that chronic OXM administration eventually results in stem cell exhaustion. The long-term repopulating ability of stem cells from OXM-treated mice was significantly lower than those of placebo-treated controls. This was not unexpected, given the fact that multiple genetic mutations associated with reduced stem cell quiescence have been shown to result in eventual stem cell depletion ([@bib26]). We have previously shown that FA HSPCs already have an accelerated cell cycle and interpreted this finding as a homeostatic mechanism that compensates for the increased loss of stem cells in this disease ([@bib40]). The administration of OXM can further enhance this compensatory mechanism, at least temporarily, and indeed does improve multiple hematological parameters in FA mice. However, our data predict that OXM will not provide a permanent rescue of hematopoiesis and that a more definitive method of treatment will be eventually needed, even in good early responders. In fact, many FA patients eventually become androgen resistant even if their initial response was positive ([@bib31]). It is possible that HSCs in these patients have been completely depleted at later stage of the treatment.

The analysis of the transcriptome of OXM-treated HSPCs was revealing. First, the data showed very clearly that the mRNA levels of *mTERT* were not different between treated and untreated animals. In vitro studies by others have shown that OXM can enhance telomerase activity through estrogen receptor-mediated signaling in short-term assays ([@bib2]). However, this effect was not observed in the long-term in vivo studies described herein. Furthermore, enhanced expression of telomerase, even if present, would not explain the observed effect on stem cell quiescence. We conclude that increased telomerase activity is not the primary mechanism by which OXM acts in vivo. Second, the RNA expression data confirmed that the cell cycle was changed by OXM at the transcriptional level. For example, the mRNA encoding the KI67 antigen was clearly induced. More importantly, however, the data demonstrated a profound (∼10-fold) decrease in osteopontin mRNA. This effect of OXM on osteopontin transcription was AR dependent and likely mediated directly by an AR-target site in *Spp1* gene. This finding has clinical implications because it indicates that the use of AR antagonists ([@bib8]) is not a viable strategy to ameliorate the masculinizing side effects of androgens in bone marrow failure patients.

Although osteopontin is best known as a protein found in bone ([@bib25; @bib35]), it is expressed at robust levels in the stem cells themselves, as evidenced by our RNA-Seq analysis of KSL cells and previously published gene expression database on SPKSL cells ([@bib3]) ([Figure S6](#app3){ref-type="sec"}). Its precise function in HSPCs is unclear, but it has been shown that *Spp1*^*−/−*^ stem cells have an accelerated cell cycle ([@bib25]). It has generally been thought that osteopontin expressed by bone cells in the HSC niche acts on stem cells in a paracrine mode ([@bib25; @bib35]). Our data indicate that this protein may also have a cell autonomous effect in stem cells. Future studies with cell-type specific knockouts will be required to address this hypothesis. A second gene, *Oasl2,* was also suppressed by OXM. *Oasl2* (2′-5′ oligoadenylate synthetase-like 2), has not been well studied in HSPCs, despite its known high expression in hematopoietic tissues ([@bib12; @bib38]). Our RNA-Seq data further showed that *Oasl2* expression was 11-fold higher in KSL cells than that in whole bone marrow cells. Several publications have identified its proapoptotic and antiproliferative roles in other cell types ([@bib11; @bib18]), but its high expression level in KSL cells suggests that it might have a direct role in HSPC function. As a cytokine, osteopontin upregulates the expression of interferons and interleukins. Conversely, *Oasl2* is known to be induced by interferons ([@bib14]), promote apoptosis, and suppress proliferation ([@bib11; @bib18]). Collectively, it is tempting to speculate that osteopontin and 2′-5′ oligoadenylate synthetase-like 2 function in the same pathway to inhibit HSPC proliferation. OXM's primary mode of action would be to transcriptionally repress this growth inhibitory pathway.

Many publications have suggested that overexpression of osteopontin may play a role in the biology of some cancers, including acute myelogenous leukemia ([@bib1; @bib21]), and that its suppression could be therapeutically beneficial. Our data suggest that OXM or other androgens could readily be used for this purpose. OXM should be tested in preclinical animal models of relevant tumors to determine whether it impairs tumor growth.

Our results also shed light on another hypothesis regarding the mechanism of action of androgens in anemia. Early work suggested that androgens stimulate erythropoiesis via the activation of EPO pathway. However, subsequent studies found no correlation between serum EPO and androgen levels ([@bib4]). Similarly, we also observed no difference in serum EPO levels between OXM- and placebo-treated mice, despite finding a substantial increase in renal mass in OXM-treated mice, a phenomenon well known to be associated with chronic androgen administration ([@bib32]). Consistent with this, RNA-Seq transcriptome analysis of early erythroid progenitors did not show any induction of critical EPO-inducible genes or EPO target genes after OXM treatment. Moreover, under our experimental conditions, OXM reduced the MCV level whereas EPO causes macrocytosis, indicating a clear divergence between the action of the two. Our data therefore argue strongly against an EPO-mediated mechanism of action for androgen therapy.

Our data also provide information on the pathophysiology of FA itself. First, we found that the drastic acceleration of cell cycling observed in *Fancd2*^*−/−*^ HSPCs is unique to this blood cell population. No cell cycle abnormalities were observed in mature hematopoietic lineages. Others have found that the hypersensitivity of FA cells to acetaldehyde is also uniquely limited to HSPCs ([@bib9]) and that it is possible that the lack of stem cell quiescence is mediated by aldehyde toxicity. Unfortunately, OXM had no effect on the expression of any aldehyde-detoxifying genes in stem cells, including *Aldh2*. Second, in the past, FA mouse models have been considered to be poor models of the human disease because they did not develop readily detectable anemia. Our results, however, indicate that *Fancd2*^*−/−*^ mice actually recapitulate the disease rather faithfully when the animals are observed for a longer time period commensurate with the time it takes to develop anemia in humans. We observed clear declines in platelet counts, obvious red cell abnormalities, including macrocytosis, and even osteopetrosis. We also found that OXM therapy had similar effects to those reported in human FA patients, improving platelet counts, red blood cell counts, and hemoglobin levels, with no changes in white blood cell counts. Overall, we conclude that aged *Fancd2*^*−/−*^ mutant mice are an adequate model for spontaneous bone marrow failure and can be used for preclinical drug efficacy studies.

Finally and most importantly, we found critical gene expression changes in HSPCs of *Fancd2* mutant mice. The changes in cell cycle-related genes and genes involved in DNA damage responses were not surprising, given the obvious lack of stem cell quiescence and the known role of the FA pathway in DNA repair ([@bib17]). However, we also found significant changes in multiple genes involved in immune responses. Recent work has clearly shown that DNA damage can activate innate immunity ([@bib10]) by signals emanating from the damaged cell. Abnormalities in cytokine sensitivity and cytokine levels have long been known to be present in FA ([@bib24]). We therefore hypothesize that some genes upregulated in FA HSPCs may be part of an innate immune response to DNA damage. In this model, DNA damage-mediated signals originating from stem cells eventually activate systemic inflammation and cytokine elevations. These proinflammatory cytokines can be toxic to stem cells and cause further genomic damage, thus creating a vicious circle resulting in bone marrow failure.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

*Fancd2* mutant, *Fancc* mutant, and *ROSA26* transgenic mice were maintained on the 129S4 strain background as described before ([@bib40]). *AR*^*−/−*^ mice were originally developed in Dr. Kato's lab and maintained on the C57BL/6J background ([@bib30]). OXM was obtained from Sigma, milled into standard rodent chow at 300 mg/kg diet (Bio-Serv), and given to the mice upon weaning (3--4 weeks of age). For complete blood count and KSL frequency analyses, the treatment continued for 17 months until harvest. For cell cycle analysis and OXM biological activity, the treatment continued for 4 months; for RNA extraction, the treatment continued for 3 months. Recombinant human EPO (Procrit from Amgen) was given in three consecutive doses at 3,000 IU on day 1, 1,000 IU on day 2, and day 3. All animals were treated in accordance with the guidelines of the Institutional Animal Care and Use Committee.

Cell Culture {#sec4.2}
------------

7F2 mouse osteoblast (ATCC CRL-12557) cells were purchased from ATCC. For in vitro OXM treatment, cells were split at the ratio of 1:10 and plated with 5 μM OXM-supplemented medium. Twenty-four hours later, cells were harvested for RNA isolation with Trizol reagent.

Complete Blood Count {#sec4.3}
--------------------

Complete blood counts were measured by IDEXX Laboratories to monitor hematological parameters.

Histopathology {#sec4.4}
--------------

Bone marrow smears and peripheral blood smears were stained with Wright-Giemsa Stain (Polysciences).

Flow Cytometry {#sec4.5}
--------------

Flow cytometry experiments were performed as described previously ([@bib40]). Propidium iodide was included as a viability dye. Mouse IgG1 isotype control (for cell cycle analysis) or fluorescence minus one controls (in all the other cases) were used for gating. Cytometric data were analyzed using FlowJo software v.9.6.1 (Tree Star).

Fractionation of erythroblasts at various stages of differentiation in bone marrow was achieved by combining cell surface marker staining of CD71 and TER119 with the analysis of cell size (based on flow cytometric forward scatter intensity) ([@bib33]). Bone marrow cells were stained with FITC-conjugated antimouse CD71 and PE-Cy7-conjugated antimouse TER119. The TER119^high^/CD71^high^/FSC^high^ basophilic erythroblast fraction was sorted on a Cytopeia Influx cell sorter equipped with four lasers, allowing for excitation wavelengths of 355, 488, 561, and 633 nm.

Competitive Repopulation Assay {#sec4.6}
------------------------------

Whole bone marrow cells were isolated from OXM- or placebo-treated mice. After red cell lysis, nucleated cells were counted and mixed with competing *ROSA26* bone marrow cells for transplantation. *Fancd2*^*−/−*^ cells were mixed with *ROSA26* cells at a 3:1 ratio, whereas *Fancd2*^*+/+*^ cells were mixed with *ROSA26* at 1:1 ratio. A total of 4 million mixed cells was used for retro-orbital injection of each recipient *Fancc*^*−/−*^ mouse preconditioned with a split whole-body lethal dose of 12 Gy irradiation (6 Gy each, 4 hr apart). Six months after transplantation, DNA was extracted for quantitative real-time PCR analysis, and each original donor's contribution to peripheral blood was calculated to assess peripheral blood chimerism. PCR primers were listed in [Table S8](#app3){ref-type="sec"}.

RNA-Seq {#sec4.7}
-------

RNA was extracted using Trizol reagent (Invitrogen), followed by RNAeasy Mini Kit (QIAGEN) and DNase I treatment. RNA quality was determined by an Agilent 2100 Bioanalyzer (Agilent technology). Three samples per condition were processed to ensure sufficient power for detecting any differentially expressed genes. For KSL libraries, each sample represented total mRNA isolated from pooled KSL cells of five individual mice; for basophilic erythroblast libraries, each library represented total mRNA isolated from basophilic erythroblasts of one individual mouse.

Libraries were constructed using TruSeq RNA Sample Preparation Kit (Illumina) according to the manufacturer's instructions and sequenced as 51 base-length reads using Illumina HiSeq 2000 genome analyzer. All reads were mapped to the mouse reference genome (version mm 9) using Bowtie short read aligner software (<http://bowtie-bio.sf.net>). Data analysis was performed using EdgeR GLM algorithms ([@bib23]). Data mining and pathway analysis were carried out with the MetaCore integrated software suite (Thomson Reuters).

Serum EPO Test {#sec4.8}
--------------

Serum samples were tested for EPO levels using a mouse EPO-specific ELISA at Ani Lytics.

Statistical Analyses {#sec4.9}
--------------------

Two-tailed, unpaired Student's t tests were performed to calculate p values using Prism 6.0c software (GraphPad Software). A p value less than 0.05 was considered significant.
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Accession Numbers {#app1}
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![Eighteen-Month-Old *Fancd2*^*−/−*^ Mice Have Pancytopenia\
(A) Complete blood counts in 18-month-old *Fancd2*^*−/−*^ mutants (n = 15) and WT controls (n = 25). WBC, white blood cells; RBC, red blood cells.\
(B) Reduced bone marrow cellularity in *Fancd2*^*−/−*^ mice. Total nucleated bone marrow cells were counted for each femur bone. The data showed the relative change (as percentage) of marrow cellularity in mutant mice as compared with their littermate WT controls and represented pooled results from four pairs of mice.\
(C) *Fancd2*^*−/−*^ mice have spleen abnormalities. (Upper and middle panels) Small spleens in two mutant mice. (Lower panel) Larger spleen in a mutant mouse.\
(D) Representative blood smear pictures of *Fancd2*^*−/−*^ mice and gender-matched WT littermate controls. The blue arrow indicates a Howell-Jolly body; green arrow, polychromatic cells; orange arrow, acanthocyte; yellow arrow, lymphocyte. Original magnification ×1,000.\
(E) H&E staining of the bone sections. (Left) Longitudinal section of the trabecular bones (original magnification, ×100). (Middle and right) Longitudinal section of the cortical bones (original magnifications: middle panels, × 50; right panels, × 400).\
See also [Table S1](#app3){ref-type="sec"}.](gr1){#fig1}

![OXM Treatment Improves Hematopoiesis\
(A) OXM-treated *Fancd2*^*−/−*^ mice (n = 5) exhibited better hematologic parameters than placebo-treated *Fancd2*^*−/−*^ controls (n = 13).\
(B) OXM-treated *Fancd*^*+/+*^ mice (n = 11) had better hematologic parameters than placebo-treated *Fancd2*^*+/+*^ controls (n = 23). OXM treatment started at weaning and continued for 17 months before final harvest.\
See also [Figure S1](#app3){ref-type="sec"}.](gr2){#fig2}

![Long-Term OXM Treatment Leads to Stem Cell Exhaustion in Both *Fancd2*^*−/−*^ and WT Mice\
(A) Long-term (18 months) OXM administration in *Fancd2*^*−/−*^ mice reduced the size of bone marrow CD34^−^KSL cell population. Percentages on flow cytometry profiles were the mean of five to nine mice.\
(B) Statistical quantification of CD34^−^KSL cell proportion in whole nucleated bone marrow cells. (Left) Comparison of CD34^*−*^KSL cell frequency between 4- to 6-month-old and 18-month-old mice. (Right) Comparison of CD34^*−*^KSL cell frequency between 18-month-old mice on OXM treatment and those on placebo treatment. All the data are pooled results from multiple mice (n = 5--9 for each group).\
(C) Strategy used in the competitive repopulation experiment. IR, BM, and mo denote irradiation, bone marrow and months, respectively.\
(D) In vivo competitive repopulation of OXM-treated (or control) test donor bone marrow and *ROSA26*^*Tg/O*^ competitor bone marrow cells. Three donors were evaluated for each experimental group; % chimerism refers to the percentage of test donor-derived cells in all donor-derived cells. Results from multiple recipients (seven to nine mice per group) were pooled together for each experimental group. Data are presented as mean ± SEM.\
See also [Table S8](#app3){ref-type="sec"}.](gr3){#fig3}

![OXM Selectively Stimulates Proliferation of KSL Cells in Both *Fancd2*^*−/−*^ and *Fancd2*^*+/+*^ Mice\
(A) Representative cell cycle profiles of KSL cells from OXM-treated mice and their gender-matched placebo-treated littermate controls. Hoechst 33342 (for DNA content) and FITC-conjugated antimouse KI67 (for G0/G1 discrimination) were used in combination to distinguish cells in G0, G1, and S-G2-M phases of the cell cycle. The denoted percentage for each gate was from a typical experiment. The mean percentage of multiple mice for each group was shown in the main text.\
(B) Statistical quantification of the cell cycle analysis on KSL cells in OXM- versus placebo-treated mice. Data represent the mean values from multiple mice (n = 9 for both OXM and placebo groups of *Fancd2*^*−/−*^ mice, n = 13 for *Fancd2*^*+/+*^ placebo group, and n = 11 for *Fancd2*^*+/+*^ OXM group).\
(C) Statistical quantification of the cell cycle analysis on LIN^+^ cells in OXM- versus placebo-treated mice. Data represent the mean values from multiple mice (n = 9 for either OXM or placebo group of *Fancd2*^*−/−*^ mice, n = 11 for *Fancd2*^*+/+*^ placebo group, and n = 10 for *Fancd2*^*+/+*^ OXM group).\
See also [Figures S2](#app3){ref-type="sec"} and [S3](#app3){ref-type="sec"}.](gr4){#fig4}

![OXM Suppresses *Spp1* Transcription through the Mediation of AR\
(A) OXM suppressed *Spp1* gene expression in cultured 7F2 mouse osteoblasts. RNA input was normalized based on glyceraldehyde 3-phosphate dehydrogenase mRNA expression. The *Spp1* expression level in placebo-treated 7F2 cells was set at 1 as a reference. Data are pooled results from four independent experiments. Data are presented as mean ± SEM.\
(B) OXM suppressed *Spp1* gene expression in kidneys. Data are pooled results from multiple female mice (n = 4 for each group).\
(C) *Spp1* gene expression levels were not suppressed by OXM in the kidneys of AR-deficient mice. Data are pooled results from multiple female mice (n = 3 for each group).\
(D) OXM stimulated KSL cell proliferation through the mediation of AR. Data are pooled results from multiple mice (n = 14 for placebo *AR*^*+/+*^ group, n = 13 for OXM *AR*^*+/+*^ group, and n = 12 for either OXM or placebo group of *AR*^*−/−*^ mice). NS denotes not significant.\
See also [Figures S4](#app3){ref-type="sec"} and [S5](#app3){ref-type="sec"} and [Table S6](#app3){ref-type="sec"}.](gr5){#fig5}

###### 

Pathways Significantly Changed in *Fancd2*^*−/−*^ HSPCs as Compared with WT HSPCs

  Pathway                            Change   FDR Score[a](#tblfn1){ref-type="table-fn"}
  ---------------------------------- -------- --------------------------------------------
  Cell differentiation               down     0.001
  Cell cycle and its regulation      up       0.002
  Mitogenic signaling                down     0.016
  Nuclear receptor signaling         down     0.022
  Inflammatory and immune response   up       0.060

FDR denotes false discovery rate. The FDR cutoff for pathway analyses was set at 0.10. Detailed gene lists for some important pathways were shown in [Table S4](#app3){ref-type="sec"}. See also [Tables S2](#mmc2){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}.

###### 

Genes Differentially Changed in Both *Fancd2*^*−/−*^ and WT HSPCs in Response to OXM Administration

  Gene                                     Symbol    Gene ID        Fold Change   Q Value[a](#tblfn2){ref-type="table-fn"}
  ---------------------------------------- --------- -------------- ------------- ------------------------------------------
  Centromere protein F                     *Cenpf*   NM_001081363   1.5           0.000
  Marker of proliferation Ki-67            *Mki67*   NM_001081117   1.4           0.000
  Secreted phosphoprotein 1                *Spp1*    NM_009263      −10.5         0.025
  2′-5′ oligoadenylate synthetase-like 2   *Oasl2*   NM_011854      −1.5          0.03

Q value cutoff was set at 0.05. See also [Figure S6](#app3){ref-type="sec"} and [Tables S5](#app3){ref-type="sec"} and [S7](#app3){ref-type="sec"}.
